Shenzhen Key Laboratory of Tissue Engineering, Shenzhen Laboratory of Digital Orthopeadic Engineering, Shenzhen Second Peoples Hospital (The First Hospital Affiliated to Shenzhen University), Shenzhen, 518035, Guangdong Province, China; Guangdong Provincial Research Center for Artificial Intelligence and Digital Orthopedic Technology, Shenzhen 518035, China; Postgraduate Institution, Guangzhou Medical University, Guangzhou 511436, Guangdong Province, China.
Shenzhen Key Laboratory of Tissue Engineering, Shenzhen Laboratory of Digital Orthopeadic Engineering, Shenzhen Second Peoples Hospital (The First Hospital Affiliated to Shenzhen University), Shenzhen, 518035, Guangdong Province, China; Guangdong Provincial Research Center for Artificial Intelligence and Digital Orthopedic Technology, Shenzhen 518035, China.
Mater Sci Eng C Mater Biol Appl. 2019 Jun;99:541-551. doi: 10.1016/j.msec.2019.01.115. Epub 2019 Jan 26.
The regeneration of hyaline articular cartilage remains a major challenge due to the limited potential for cartilage to self-repair. Mesenchymal stem cell and hydrogel scaffold-based cartilage tissue engineering is a promising technique for articular cartilage therapy. The purpose of this study was to investigate the use of rabbit synovial fluid mesenchymal stem cells (rbSF-MSCs) encapsulated in an injectable chitosan-based hydrogel to repair full-thickness cartilage defects in femoral patellar grooves in rabbits. The rbSF-MSCs were obtained from rabbit synovial fluid and the surface markers of rbSF-MSCs were coincidental to the identification criteria of MSCs according to flow cytometry. The rbSF-MSCs were able to differentiate into osteogenic, adipogenic and chondrogenic lineages. In the present study, rbSF-MSCs encapsulated in glycol chitosan (GC) and benzaldehyde capped poly (ethylene oxide) (OHC-PEO-CHO) hydrogel were introduced into rabbits to repair articular cartilage defects. The modulus of the hydrogel could be regulated by the concentrations of GC and OHC-PEO-CHO and the hydrogel has a good biocompatibility to rbSF-MSCs. Assessment of in vivo repair indicates using hydrogel/rbSF-MSCs was superior to using the hydrogel scaffold only and the untreated control based on gross appearance and histological grading and evaluation. These preliminary findings suggest using the injectable chitosan-based hydrogel as a scaffold and rbSF-MSCs as seed cells is an alternative for tissue engineering of in vivo treatments for cartilage defects and these rbSF-MSCs allografts may be promising for use in clinical applications.
由于软骨自身修复的潜力有限,因此透明软骨的再生仍然是一个主要挑战。基于间充质干细胞和水凝胶支架的软骨组织工程是一种很有前途的关节软骨治疗技术。本研究旨在探讨将兔滑膜间充质干细胞(rbSF-MSCs)包封在可注射壳聚糖基水凝胶中,用于修复兔股骨滑车沟全层软骨缺损。rbSF-MSCs 从兔滑膜中获得,rbSF-MSCs 的表面标志物与流式细胞术鉴定的 MSC 标准相符。rbSF-MSCs 能够分化为成骨细胞、脂肪细胞和成软骨细胞。在本研究中,将 rbSF-MSCs 包封在乙二醇壳聚糖(GC)和苯甲醛封端的聚(环氧乙烷)(OHC-PEO-CHO)水凝胶中,用于修复关节软骨缺损。水凝胶的模量可以通过 GC 和 OHC-PEO-CHO 的浓度来调节,水凝胶对 rbSF-MSCs 具有良好的生物相容性。体内修复评估表明,基于大体观察和组织学分级和评估,使用水凝胶/rbSF-MSCs 修复优于仅使用水凝胶支架和未处理的对照组。这些初步发现表明,使用可注射壳聚糖基水凝胶作为支架和 rbSF-MSCs 作为种子细胞是治疗体内软骨缺损的组织工程的一种替代方法,这些 rbSF-MSCs 同种异体移植物可能在临床应用中具有广阔的应用前景。
Mater Sci Eng C Mater Biol Appl. 2019-1-26
Front Pharmacol. 2025-5-21
Int J Mol Sci. 2025-5-5
Front Bioeng Biotechnol. 2024-1-25
Exploration (Beijing). 2023-7-10
Curr Pharm Biotechnol. 2024
Molecules. 2023-10-12
Front Bioeng Biotechnol. 2023-2-7